National Disease Research Interchange

 David M. Albert J.D., Director of Strategy, Emerging Business & Venture Capital Group of Cozen O’Connor. Elected on November 2 to a three-year term, Albert will bring his experience and insight to the nation’s leading source of human organs, cells and tissues for research.

NDRI’s Board of Directors met on Friday, November 2, 2018 to review and approve the 2017 audited financial statements, filing of Form 990, year-to-date financial and programmatic performance and NDRI’s 2019 Budget. Our executive staff provided the Board with a detailed overview of our many successful projects and partnerships, and included an update on the current status of NIH appropriations.

NDRI is very pleased to share that after eight years of advocacy efforts by the Center for Organ Recovery and Education (CORE) and the Gift of Life Donor Program of Philadelphia, lawmakers unanimously passed the Donate Life PA Act (SB 180) on Wednesday, October 10, 2018.

Bill Leinweber, President and CEO of National Disease Research Interchange (NDRI) admits that NDRI’s work is complicated, because medical research is complex. For nearly 40 years, NDRI has accepted the challenge of meeting increasing demands of the medical research community, who rely on high-quality, healthy, and diseased biospecimens to conduct lifesaving research.

“Support from the NIH affirms the strong value of our mission,” said Gene Kopen, PhD, NDRI’s Senior Vice President for Strategic Initiatives and principal investigator for the HTORR grant. “As an organization, NDRI has demonstrated the capacity to leverage this support to enable a broad range of complex research projects requiring human organs and tissues.”